BioNTech Cancer Drug Trial Cleared by FDA
Ticker: BNTX · Form: 6-K · Filed: Aug 19, 2024 · CIK: 1776985
| Field | Detail |
|---|---|
| Company | Biontech Se (BNTX) |
| Form Type | 6-K |
| Filed Date | Aug 19, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial, fda, biotech
TL;DR
FDA lifts clinical hold on BioNTech's BNT113 cancer drug, Phase 2 trial can now proceed.
AI Summary
On August 19, 2024, BioNTech SE announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on its investigational new drug (IND) application for the mRNA-based cancer immunotherapy candidate, BNT113. This allows BioNTech to proceed with its planned Phase 2 clinical trial for BNT113 in patients with HPV-positive head and neck cancer.
Why It Matters
The FDA lifting the clinical hold allows BioNTech to advance its novel cancer immunotherapy, potentially leading to new treatment options for patients with HPV-positive head and neck cancer.
Risk Assessment
Risk Level: medium — While the clinical hold being lifted is positive, the success of the Phase 2 trial and eventual market approval are still uncertain, carrying inherent risks for drug development.
Key Players & Entities
- BioNTech SE (company) — Registrant
- U.S. Food and Drug Administration (company) — Regulatory body
- BNT113 (drug_candidate) — mRNA-based cancer immunotherapy
- August 19, 2024 (date) — Announcement date
FAQ
What specific cancer type will the Phase 2 trial for BNT113 focus on?
The Phase 2 clinical trial for BNT113 will focus on patients with HPV-positive head and neck cancer.
What was the reason for the partial clinical hold on BNT113?
The filing does not specify the exact reason for the partial clinical hold, only that it has been lifted.
What type of therapy is BNT113?
BNT113 is an mRNA-based cancer immunotherapy candidate.
When was the announcement made regarding the lifting of the clinical hold?
The announcement was made on August 19, 2024.
Which regulatory body lifted the clinical hold?
The U.S. Food and Drug Administration (FDA) lifted the partial clinical hold.
Filing Stats: 256 words · 1 min read · ~1 pages · Grade level 10.8 · Accepted 2024-08-19 08:34:28
Filing Documents
- form6-kbnt326lift19aug2024.htm (6-K) — 15KB
- a99_1240819xbntx6kfilingxb.htm (EX-99.1) — 13KB
- image_0a.jpg (GRAPHIC) — 106KB
- 0001776985-24-000075.txt ( ) — 175KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a16 OR 15d16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant's name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20F or Form 40F Form 20F Form 40F Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(1) Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(7) DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On August 19, 2024, BioNTech SE issued a website statement announcing that the U.S. Food and Drug Administration has lifted the partial clinical hold that was placed on the MediLink Therapeutics (Suzhou) Co., Ltd. Phase I trial evaluating BNT326YL202 (NCT05653752). The statement is attached hereto as Exhibit 99.1. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By s Jens Holstein By s Dr. Sierk Poetting Name Jens Holstein Name Dr. Sierk Poetting Title Chief Financial Officer Title Chief Operating Officer Date August 19, 2024 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 Lift of Partial Clinical Hold for BNT326YL202